[2-丁基-5-氯-1-[(2-氯苯基)甲基]咪唑-4-基]甲基乙酸酯 | 131549-86-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: [2-丁基-5-氯-1-[(2-氯苯基)甲基]咪唑-4-基]甲基乙酸酯
• 英文名称: [2-Butyl-5-chloro-1-(2-chlorobenzyl)-1h-imidazol-4-yl]methyl acetate
• 英文别名: [2-butyl-5-chloro-1-[(2-chlorophenyl)methyl]imidazol-4-yl]methyl acetate
• CAS: 131549-86-5
• 化学式: C₁₇H₂₀Cl₂N₂O₂
• 分子量: 355.3
• InChiKey: WBFAHXKJEZSANA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES
  申请人：Forssmann Wolf-Georg

  公开号：US20120172365A1

  公开（公告）日：2012-07-05

  The present invention pertains to the use of inhibitors of phosphodiesterase I, IV and V for the prophylaxis and treatment of prostatic diseases, in particular the use of a) 2-(2-propoxy- phenyl)-8-azapurin-6-one (zaprinast); b) dipyridamole; c) 1-(3-chlorophenylamino)-4-phenylphthalazine (M5445); d) 2-(N-(4-carboxypiperidine-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355); e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol, alpha-nitrate (E 4701); f) 4-((3,4-(methylendioxy)benzyl)amino)-6,7,8-trimethoxy-quinazoline; g) 1-methly-3-propyl-6-(5-(N-(4-methylmorpholino)sulfonyl)-2-ethoxyphenyl)pyrazole[4,5]pyrimidin-4(5H)one (sildenafil); i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo(3,4-d)pyrimidin-4(5H)-one (WIN 58237); j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxypropoxy)-2-carboxy-2,3-didehydro-chronan-4-one (PPL-557212); k). quinazolines and their trimethoxy derivatives; l) Pyrazolopyrimidones; as well as pharmacologically compatible salts thereof, quinazolines and their trimethoxy derivatives, pyrazolopyrimidones or compatible salts thereof, in local and systemic administration.
• US8106061B2
  申请人：——

  公开号：US8106061B2

  公开（公告）日：2012-01-31
• US8791124B2
  申请人：——

  公开号：US8791124B2

  公开（公告）日：2014-07-29